CUMBERLAND PHARMACEUTICALS INC (CPIX): debt financing — Cumberland amends credit line: reduces revolver to $15M, extends maturity to Oct 2027

CUMBERLAND PHARMACEUTICALS INC

Principal available reduced to $15M (from $20M); right to request additional $10M (up from $5M).
Maturity extended to October 1, 2027; interest rate is Benchmark Term SOFR + 2.75%.
New financial covenant: Minimum Fixed Charge Coverage Ratio of 1.75x, replacing Maximum Funded Debt Ratio.
Borrowing Base Requirements made permanent; company paid $15,000 amendment fee.
Collateral remains substantially all assets; credit line with Pinnacle Bank.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

CUMBERLAND PHARMACEUTICALS INC incurred revolving credit of up to $15 million with Pinnacle Bank at Benchmark Term SOFR plus 2.75% maturing October 1, 2027.

Instrument: revolving credit
Principal: up to $15 million
Counterparty: Pinnacle Bank
Rate: Benchmark Term SOFR plus 2.75%
Maturity: October 1, 2027
Event: incurrence

Exact text from the filing

The Amendment provides for a principal available for borrowing of up to $15 million.

View on SEC.gov

311 debt financings filed in the last 30 days. Browse all debt financings →

CUMBERLAND PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001087294-25-000023

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.